David W. Parke

Genomatica, Inc. designs and develops biotechnology products. It offers metabolic engineering for renewable production of commodity chemicals. The company was founded by Bernhard O. Palsson and Christophe H. Schilling in 1998 and is headquartered in San Diego, CA.

DNAnexus, Inc. develops a cloud-based data analysis and management platform for DNA sequence data. It engages in the provision of cloud-based solutions for large-scale Deoxyribonucleic acid (DNA) data management and analysis. The firm offers a centralized hub for managing data, collaborating with other scientists, sharing tools, and accessing diverse reference datasets, including genotypic and phenotypic data. The company was founded by Serafim Batzoglou, Andreas Sundquist and Arend Sidow in 2009 and is headquartered in Mountain View, CA.

Element Science, Inc. operates as a medical device and digital health company. It develops a wearable platform solution with proprietary technology in wearable patches, electrical design, machine learning algorithms and digital solutions. The company was founded by Uday N. Kumar in 2011 and is headquartered in San Francisco, CA.

Quartet Health, Inc. provides software and solutions for behavioral health providers and patients. Its suite of products enables a proven model that integrates care for patients with chronic medical and behavioral health conditions. The firm has developed a secure, cloud-based technology platform that addresses the problem of access to behavioral health care resources. The company was founded by Arun Gupta and Steven J. Shulman in 2014 and is headquartered in New York, NY.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Kleiner Perkins Caufield & Byers LLC (Kleiner Perkins Caufield & Byers) is a venture capital firm founded in 1972 by Eugene Kleiner, Thomas Perkins, Brook Byers and Frank J. Caufield. The firm is headquartered in California, US.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA.

SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO.

GV Management Co LLC (Google Ventures) is a venture capital firm, a subsidiary of Google LLC founded in 2009 by Bill Maris. The firm is headquartered in Mountain View, California with an additional office in San Francisco, Boston, New York and London.

Flatiron Health, Inc. develops health care technology. Its OncologyCloud platform allows cancer centers, physicians and life science companies to gain actionable insights from clinical, practice management and billing data. The firm's software platform accelerates personalized medicine and research by applying advanced analytics to electronic patient care data documented by physicians. The company was founded by Nathaniel S. Turner and Zachary W. Weinberg in 2012 and is headquartered in New York, NY.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Ophthalmic Mutual Insurance Co. (Investment Portfolio) (OMIC-IP) is the investment portfolio division of Ophthalmic Mutual Insurance Co., a mutual insurance company headquartered in San Francisco, California. The firm was founded in 1987 by a group of visionary eye doctors and they provide high quality medical liability insurance products and services to members of the American Academy of Ophthalmology. OMIC-IP manages the insurance portfolio.

Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA.

PatientPing Inc. provides healthcare services. The firm develops a national care coordination network that connects healthcare providers with real-time notifications wherever patients receive care. The company was founded by Lara Sinicropi Yao, David Berkowicz and Jay Desai in September 2013 and is headquartered in Boston, MA.

Imagen Technologies, Inc. operates as a medical technology company that develops and offers devices for the prevention of diagnostic errors. The company was founded by Alexander Dresner, Robert Lindsey, Thomas Stuart Hotchkiss and Sumit Chopra in 2015 and is headquartered in New York, NY.

One Medical Group, Inc. provides healthcare services. The firm's services include dermatology, family medicine, flu shot, mental health, nutrition, on-site labs, pediatrics, prenatal care, primary care, same-day care, sports medicine, travel health and women's health. The company was founded by Thomas H. Lee and is headquartered in San Francisco, CA.

Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA.

LifeMine Therapeutics, Inc. develops drugs from fungi which aims to cure untreatable and significant chronic diseases. The company was founded by Gregory L. Verdine, WeiQing Zhou, Richard D. Klausner and Hingge Hsu and is headquartered in Cambridge, MA.

Paige Ai, Inc. engages in revolutionizing pathology and strengthen lynchpin of medical diagnostics with quantitative, computational technology, fusing machine learning, and human expertise. It involves in building an artificial intelligence to change clinical diagnosis and treatment of cancer. The company is headquartered in New York, NY.

Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA.

Sexton Biotechnologies, Inc. operates biotechnology company which develops and sales of bio-production tools for cell and gene therapy. The company is headquartered in Indianapolis, IN.

Mnemo Therapeutics SAS is a French biotechnology company that develops cell therapies to create accessible cures for cancer patients. The company is based in Paris, FR, and has subsidiaries in the United States. The company applies a novel approach to cell therapy using its enfinit platform, a groundbreaking drug discovery engine. Mnemo is committed to addressing the challenges in the field of immuno-oncology, such as a lack of cancer-specific targets, long-term persistence, and sensitivity. The company aims to engineer the future of immunotherapies to transform the lives of people with cancer by discovering novel cancer-specific targets and boosting immune activity to treat solid tumors. The company was founded in 2019 by Alain Maïore and Michel Sadelain. Robert LaCaze has been the CEO of the company since 2022.

IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.